But the process may take months, pending Congressional approval.
NIAID's Carl Dieffenbach, Ph.D., joins Anne Rancourt to discuss some key takeaways from the 10th International AIDS Society Conference on HIV Science.
As the 2020 presidential hopeful touts her HIV activist record, doubts remain as to whether her version of events is the full truth.
Use these guidelines proposed by a pair of expert physicians in the U.S. to advocate for your health care.
Our new "Eyes on the End" series kicks off with an up-close-and-personal glimpse at what's driving the HIV epidemic in the Atlanta metropolitan area.
Creating stigma for abortions may have a chilling effect on those seeking any sexual health care.
What would you be willing to pay for a cure for HIV? We bring you five fresh perspectives, from science to the streets.
What's an opportunistic infection? It's a disease that preys on people with weak immune systems. That's what makes it an opportunist.
Fortunately, people with HIV who are taking therapy can go a long time before they suffer the immune damage that ...
The pharmaceutical industry just doesn't get it. Here we are on the cusp of a revolution in medicine, with genomic insights likely to yield a generation of medicinal products safer and more effective than any before; with burgeoning markets, record p...